Amerikanische Gesellschaft für Hirudotherapie

An optimized method to assess in vivo efficacy of antithrombotic drugs using optical coherence tomography and a modified Doppler flow system

Research article published in Journal of pharmacological and toxicological methods (2011)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)ArzneimittelentwicklungCouture L et al. · Journal of pharmacological and toxicological methods, 2011

Abstract

INTRODUCTION: Animal models of venous and arterial thrombosis are extremely useful to study the efficacy of antithrombotic agents. Variability in efficacy data is often observed in those preclinical studies. The goal of this study was to optimize the methodology for assessing antithrombotic drug efficacy by the use of optical coherence tomography (OCT) and a modified Doppler flow system in rat models of thrombosis. METHODS: Thrombus formation was assessed in both the rat venous and arterial ferric chloride (FeCl(3)) models of thrombosis. In the venous model, thrombus volume post-treatment was measured using OCT, and data were correlated against the thrombus weight. In the arterial model, the time to occlusion was measured using a Doppler flow probe connected to a perivascular flow module which allowed the reporting of dynamic blood flow data every 30s. Heparin (130 or 165U/kg), argatroban (4.5mg/kg), bivalirudin (1.3mg/kg) or saline were administered intravenously. RESULTS: In the venous model, for all treatment groups a strong linear correlation (R(2)=0.998) was observed between thrombus volume measured by OCT and thrombus weight. In the arterial model, using a high sampling rate of a dynamic blood flow using a modified Doppler flow system provided data accuracy and precision of the time to occlusion measurement. DISCUSSION: This study demonstrates that OCT is a powerful tool for the assessment of antithrombotic drug efficacy. Furthermore, it shows that a high Doppler sampling rates of dynamic blood flow leads to data accuracy and precision.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsArginineDrug Evaluation, PreclinicalFibrinolytic AgentsHeparinHirudinsLaser-Doppler FlowmetryMalePeptide FragmentsPipecolic AcidsRatsRats, Sprague-Dawley

Zusammenfassung

Animal models of venous and arterial thrombosis are extremely useful to study the efficacy of antithrombotic agents.

Warum dies für die Hirudotherapie relevant ist

This methodological study optimized assessment of antithrombotic drug efficacy using optical coherence tomography (OCT) and a modified Doppler flow system in rat FeCl₃-induced venous and arterial thrombosis models. Heparin, argatroban, bivalirudin, or saline were administered intravenously as test treatments; a strong linear correlation (R²=0.998) between OCT-measured thrombus volume and thrombus weight was demonstrated in the venous model, and the modified Doppler system provided accurate and precise time-to-occlusion measurement in the arterial model. No defensible leech or hirudotherapy link exists in this abstract: bivalirudin is listed among test drugs but the abstract provides no characterization connecting it to hirudin or leeches. The study's purpose is imaging methodology validation for preclinical antithrombotic assessment.

Zitation

An optimized method to assess in vivo efficacy of antithrombotic drugs using optical coherence tomography and a modified Doppler flow system

Couture L et al. · Journal of pharmacological and toxicological methods, 2011

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.